Tuberc Respir Dis > Volume 37(3); 1990 > Article
Tuberculosis and Respiratory Diseases 1990;37(3):288-293.
DOI: https://doi.org/10.4046/trd.1990.37.3.288    Published online September 1, 1990.
Relationship between Changes of the Value of s-AST/ALT and Serologic Markers for Hepatitis B Virus during Anti-tuberculosis (HRE) Treatment
Kyung Sun Son1, Nam Jae Kim1, Ji Won Suhr1, Yeon Chae Jeong1, Ju Ock Kim1, Sun Young Kim1, Kyoung Joo Rhee2
1Department of Internal Medicine, College of Medicine, Chungnam National University, Chungnâm, Koreae
2Department of Internal Medicine, Daejeon Eulji Hospital, Daejeon, Koreae
항결핵 삼제요법(HRE) 중 혈청 AST/ALT의 상승과 B형 간염의 혈청학적 지표와의 관계
손경선1, 김남재1, 서지원1, 정연채1, 김주옥1, 김선영1, 이경주2
Abstract
A clinical study was performed in 272 patients who had pulmonary tuberculosis to evaluate the relationship between changes of the value of s.AST / ALT and serologic markers for hepatitis B virus during anti-tuberculous treatment with three drug regimen of isoniazid (INH), rifampicin (RFP), and ethambutol (EMB).
Results
were as follows: 1) Among the 272 pulmonary tuberculosis patients, 54 patients had HBsAg (+), 82 patients had HBsAb (+), and 136 patients had HBsAg (-) & HBsAb (-). 2) During the antituberculous chemotherapy, s.AST/ALT were elevated in 48 (17.6%) patients. Among the 54 patients with HBsAg, 10 patients (18.5%) showed elevation of s.AST/ ALT; among 83 patients with HBsAb, 13 patients (15.9%) showed s.AST/ ALT elevation; and among 136 patients without HBsAg & HBsAb, 25 patients (18.4%) showed s.AST/ ALT elevation. 3) There was no statistical significance between the time and degree of s.AST/ ALT elevation. 4) Treatment interruption occurred in 2 patients due to the marked elevation of s.AST/ ALT . One patient was HBsAg.positive and the other was negative in HBsAg & HBsAb. As a result of this study, we concluded that the relationship between changes of the value of s-AST / ALT and serologic markers for hepatitis B virus was not significantly different among each group of patients with HBsAg, HBsAb, and without HBsAg & HBsAb during antituberculous treatment with isoniazid, rifampicin, and ethamutol (HRE) regimen.


ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
FOR CONTRIBUTORS
Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail: katrdsubmit@lungkorea.org                

Copyright © 2024 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next